Navigation Links
Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
Date:5/6/2008

BERKELEY HEIGHTS, N.J., May 6 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced today that it has been advised that the Financial Industry Regulatory Authority (FINRA, formerly, the NASD) has cleared a market maker's Form 211 application to quote the Company's stock on the Over-the-Counter Bulletin Board (OTCBB). As a result, the Company expects that trading and quotations for the Company's common stock will begin on Wednesday, May 7, 2008. The Company's trading symbol will remain GNTA.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi- synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

About the OTC Bulletin Board

The OTC Bulletin Board (
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
2. Dr. Elizabeth Brown Joins Argenta TEC
3. Syngenta To Build Major Global Biotech Research Center in Beijing, China
4. Genta Restructures Operations to Focus on Priority Initiatives
5. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
6. Auditors for Genta Incorporated Express Going Concern Qualification
7. Genta Announces Senior Management Changes
8. Genta Announces Common Stock Offering of Approximately $3.1 Million
9. Genta Incorporated to Present at the BIO CEO & Investor Conference
10. Genta Receives Notice of Non-Compliance With NASDAQ Rule
11. Genta Receives NASDAQ Non-Compliance Notice
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2
Other Biology Technology:Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting 2Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting 3Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting 4Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities 2Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities 3Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities 4Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities 5CryoLife Reports Record First Quarter Revenues of $26.7 Million 2CryoLife Reports Record First Quarter Revenues of $26.7 Million 3CryoLife Reports Record First Quarter Revenues of $26.7 Million 4CryoLife Reports Record First Quarter Revenues of $26.7 Million 5CryoLife Reports Record First Quarter Revenues of $26.7 Million 6CryoLife Reports Record First Quarter Revenues of $26.7 Million 7CryoLife Reports Record First Quarter Revenues of $26.7 Million 8CryoLife Reports Record First Quarter Revenues of $26.7 Million 9CryoLife Reports Record First Quarter Revenues of $26.7 Million 10